Pharmakologie und antihypertensive Wirksamkeit der Kalziumantagonisten

Überblick für die Praxis
  • E. Fritschka
  • M. Claus
  • Th. Philipp
Chapter
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

Für die Praxis stehen Kalziumantagonisten vom Dihydropyridin-, Verapamil- und Diltiazemtyp mit sehr unterschiedlichen pharmakokinetischen Eigenschaften zur Verfügung. Der Zeitpunkt der maximalen Plasmaspiegel nach oraler Einnahme reicht von 0,5–1 h bis zu 8–9 h. Die Plasmahalbwertszeiten liegen zwischen 2–3 h und 35–50 h. Einige Kalziumantagonisten liegen sowohl in rasch resorbierbarer als auch in retardierter Form vor.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Åberg H, Lindsjo M, Morlin B (1984) Comparative trial of felodipine and nifedipine in refractory hypertension. Drugs 29 [suppl 2]: 117Google Scholar
  2. Abernethy DR, Montamat SC (1987) Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. Am J Cardiol 60: 1161–1201Google Scholar
  3. Abernethy DR, Gutkowska J, Lambert MD (1988 a) Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 12 [suppl 7]:S67–S71Google Scholar
  4. Abernethy DR, Schwartz JB (1988 b) Pharmacokinetics of calcium antagonists under development. Clin Pharmacokinet 15: 1–14Google Scholar
  5. Ahmad S (1984) Nifedipin-phenytoin interaction. J Am Coll Cardiol 3: 1582PubMedGoogle Scholar
  6. Ahr G, Wingeder W, Kuhlmann J (1987) Pharmacokinetics of nisoldipine. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 59–66Google Scholar
  7. Ahr HJ, Krause HP, Suwelack D, Weber H (1988) Pharmacokinetics of nisoldipine. 2. Distribution to and elimination from tissues and organs following single or repeated administration of 14C-Nisoldipine to rats and dogs. Arzneimittelforschung 38 (8): 1099–1104PubMedGoogle Scholar
  8. Akhtar M, Tchou P, Jazayeri M (1989) Use of calcium channel blockers in the treatment of cardiac arrhythmias. Circulation 80 [supp. 1]:IV31–IV39PubMedGoogle Scholar
  9. Akioka A, Kohno M, Nishikimi T, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T (1987) Influence of nisoldipine on hemodynamics and atrial natriuretic polypeptides at exercise loading in hypertensive patients. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 159–164Google Scholar
  10. Alaoui Jamah MA, Yin MB, Mazzoni A, Bankusli I, Rustum YM (1989) Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog ROl 1–2933. Cancer Chemother Pharmacol 25: 77–83Google Scholar
  11. Alker D, Campbell SF, Cross PE, Burges RA, Carter AJ, Gardiner DG (1990) Long-acting dihydropyridine Kalzium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and non basic derivatives of 2-((2-aminoethoxy)methyl)-l,4-dihydropyridine calcium antagonists. J Med Chem 33: 585–591PubMedGoogle Scholar
  12. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DPJ, Hundley MB, Johnson RK, Strom JA, Transou CR (1983) Cerebral arterial spasm - a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624PubMedGoogle Scholar
  13. Anavekar SN, Christophidis N, Louis WJ, Doyle AE (1981) Verapamil in the treatment of hypertension. J Cardiovasc Pharmacol 3: 287–292PubMedGoogle Scholar
  14. Anderson S (1989) Antihypertensive therapy and the progression of renal disease. J Hypertens 7 [suppl 7]: S39–S42Google Scholar
  15. Andersson OK, Bengtsson C, Elmfeldt D, Haglund K, Hedner T, Seideman P, Sjöberg K-H, Strömgren E, Åberg H, Östman J (1984) Short-term effects of felodipine, a new dihydropyridine, in hypertension. Br J Clin Pharmacol 17: 257–263PubMedGoogle Scholar
  16. Andersson OK, Granerus G, Hedner T, Wysocki M (1985) Systemic and renal hemodynamic effects of single oral doses of felodipine in patients with refractory hypertension receiving chronic therapy with beta-blockers and diuretics. J Cardiovasc Pharmacol 7: 544–549PubMedGoogle Scholar
  17. Andersson OK, Persson B, Hedner T, Aurell M, Wysocki M (1989) Blood pressure control and hemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men. J Hypertens 7: 465–469PubMedGoogle Scholar
  18. Andren L, Hansson L, Orö L, Ryman T (1982) Experience with nitrendipine - a new calcium antagonist - in hypertension. J Cardiovasc Pharmacol 4: S387–S391PubMedGoogle Scholar
  19. Aronoff GR (1984) Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects. J Cardiovasc Pharmacol 6 [suppl 7]: S974–S976PubMedGoogle Scholar
  20. Aronoff GR (1985) Nitrendipine kinetics in normal and impaired renal function. Clin Pharmacol Ther 38: 212–218PubMedGoogle Scholar
  21. Asanuma K (1978) Clinical use of diltiazem hydrochloride (Herbesser®) in the treament of hypertension. Mod Clin Med 20: 1081 (in Japanese)Google Scholar
  22. Austin MD, Robson RA, Bailey PR (1983) Effect of nifedipine on renal function of normal subjects and hypertensive patients with renal functional impairment. N Z Med J 96: 829Google Scholar
  23. Bäärnhielm C, Skånberg I, Bork KO (1984) Cytochrome P-450-dependent oxidation of felodipine - a 1,4-dihydropyridine - to the corresponding pyridine. Xenobiotica 14: 719–726PubMedGoogle Scholar
  24. Baha S, Satoh T, Bushi T et al. (1988) Drug interplay between digitalis and calcium antagonists. Jpn J Clin Pharmacol Ther (Rinsho-Yakuri) 19: 291–292Google Scholar
  25. Barbarash RA, Baumann JL, Fischer JH, Kondos GD, Batenhorst RL (1988) Near total reduction in verapamil bioavailability by rifampin. Chest 94: 954–959PubMedGoogle Scholar
  26. Bauer JH, Reams G (1987) Short- and long-term effects of calcium entry blockers on the kidney. Am J Cardiol 59: 66A–71APubMedGoogle Scholar
  27. Been M et al. (1985) Electrophysiological effects of felodipine. Drugs 29 [suppl 2]: 76–80PubMedGoogle Scholar
  28. Beer N, Gallegos I, Cohen A, Klein N, Sonnenblick E, Frishman W (1981) Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension. Chest 79: 571PubMedGoogle Scholar
  29. Bengtsson-Hasselgren B, Elmfeldt D, Moberg L, Ronn O (1989) Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol. Eur J Clin Pharmacol 37: 459–465PubMedGoogle Scholar
  30. Berdeaux A (1989) Arterial baroreceptor reflex and calcium antagonists. Fundam Clin Pharmacol 3 [suppl]: 65s–70sPubMedGoogle Scholar
  31. Bernini F, Catapano AL, Corsini A, Fumagalli R, Paoletti R (1989) Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol 64: 1291–1331Google Scholar
  32. Bertel O, Conen D, Radu EW, Muller J, Lang C, Dubach UC (1983) Nifedipine in hypertensive emergencies. Brit J Med 286: 19Google Scholar
  33. Bevan JA, Kaminow L, Laher I, Thompson LP (1989) Pharmacology of TA-3090 (8-chloro diltiazem) related to its cerebrovascular protective properties. Circulation 80 [suppl]:IV178–IV183PubMedGoogle Scholar
  34. Black HR, Vlachakis N (1984) Once and twice daily nitrendipine therapy in essential hypertension. In: Scriabine A, Vanov S, Deck K (eds) Nitrendipine. Urban & Schwarzenberg, Baltimore München, pp 509–518Google Scholar
  35. Blaehr H, Friis S (1990) Acute inhibition of human renal tubular cell growth by cyclosporine A. Pharmacol Toxicol 66: 115–120PubMedGoogle Scholar
  36. Boelaert J, Valcke Y, Dammekens H, Vriese G DE, Ahr G (1988) Pharmacokinetics of Nisoldipine in renal dysfunction. Eur J Clin Pharmacol 34: 207–209PubMedGoogle Scholar
  37. Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF, Cledes J (1986) Nicardipine increases cyclosporine blood levels. Lancet 1: 1447PubMedGoogle Scholar
  38. Brigden G, Heber M, Caruana M, Lahiri A, Raftery EB (1989) Once daily nisoldipine in hypertension: cuff and ambulatory intraarterial blood pressure. Eur J Clin Pharmacol 37: 551–554PubMedGoogle Scholar
  39. Brittinger WD, Schwarzbeck A, Wittenmeier KW et al. (1970) Klinisch experimentelle Untersuchungen über die blutdrucksenkende Wirkung von Verapamil. Dtsch Med Wochenschr 95: 1871–1877PubMedGoogle Scholar
  40. Brügmann U, Luther M (1988) The antüschemic effect of modern calcium antagonists. Fortschr Med 106 (18): 48–52Google Scholar
  41. Bruno NA, Slate DL (1990) Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrugresistant cells. J Natl Cancer Inst 82: 419–424PubMedGoogle Scholar
  42. Bühler FR, Hulthén UL, Kiowski W, et al. (1982) The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 4: 350–357Google Scholar
  43. Burges RA, Dodd MG, Gardiner DG (1989) Pharmacologic profile of amlodipine. Am J Cardiol 64: 101–181Google Scholar
  44. Bursztyn M, Grossmann E, Rosenthal T (1985) Long-acting nifedipine in moderate and severe hypertensive patients with serious concomitant disease. Am Heart J 110 (Pt I): 96PubMedGoogle Scholar
  45. Bussmann WD, Hopf R (1985) Kalziumantagonisten in der Therapie der koronaren Herzerkrankung. Inn Med 12: 255–258Google Scholar
  46. Cagatay M, Frost N, Weiss KH, Wiesner K (1987) Assessment of long-term efficacy and tolerability of nisoldipine by the clinical data pool. In: Hugenholtz PG, Meyer J (eds) Nisoldipine. Springer, Berlin Heidelberg New York Tokyo, pp 201–209Google Scholar
  47. Capewell S, Freestone S, Critchley JA, Pottage A, Prescott LF (1988) Reduced bioavailability in patients taking anticonvulsants. Lancet 11: 480–482Google Scholar
  48. Carruthers G, Bailey D (1987) Tolerance and cardiovascular effect of single dose felodipine/betablocker combinations in healthy subjects. J Cardiovasc Pharmacol 10 [suppl 1]: 5Google Scholar
  49. Casellas D, Moore LC (1990) Autoregulation and tubuloglomerular feedback in juxtamedullary glomerular arterioles. Am J Physiol 258: F660–F669PubMedGoogle Scholar
  50. Catterall WA (1988) Structure and function of voltage-sensitive ion channels. Science 242: 50–61PubMedGoogle Scholar
  51. Challenor VF, Waller DG, Renwick AG, Gruchy BS, George CF (1987) The trans-hepatic extraction of nifedipine. Br J Clin Pharmacol 24: 473–477PubMedGoogle Scholar
  52. Chandler MHH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA (1988) The effects of renal function on the disposition of isradipine. J Clin Pharmacol 28: 1076–1080PubMedGoogle Scholar
  53. Chellingsworth MC, Willis JV, Jack DB, Kendall MJ (1988) Pharmacokinetics and pharmacodynamics of isradipine (PN 200–110) in young and elderly patients. Am J Med 84 [suppl 3B]: 72–79Google Scholar
  54. Cheung WK, Sia LL, Woodward DL, Graveline JF, Desjardins RE, Yacobi A, Silber BM (1988 a) Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. J Clin Pharmacol 28: 1000–1007Google Scholar
  55. Cheung WK, Woodward DL, Shin K, Hibberd M, Silber BM (1988b) Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers. Int J Clin Pharmacol Res 8: 299–305PubMedGoogle Scholar
  56. Cheung WK, Sia LL, Hibberd M, Pearse S, Woodward DL, Desjardins RE, Bernstein J, Yacobi A, Silber BM (1989) Pharmacokinetics of nilvadipine after multiple oral dosing to steady state. Drug Development and Industrial Pharmacy 15: 51–63Google Scholar
  57. Clair F, Bellet M, Guerret M, Drueke T, Grunfeld JP (1985) Hypotensive effects and pharmacokinetics of nicardipine in patients with severe renal failure. Curr Therapeutic Res 28: 74–82Google Scholar
  58. Clifton GD, Blouin RA, Dilea C, Schran HF, Hassell AE, Gonasun LM, Foster TS (1988) The pharmacokinetics of oral isradipine in normal volunteers. J Clin Pharmacol 28: 36–42PubMedGoogle Scholar
  59. Collste P, Danielsson M, Elmfeldt D et al. (1985) Long-term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension. Drugs 29 [suppl 2]: 124–130PubMedGoogle Scholar
  60. Cooperative Study Group (1986) Felodipine versus hydralazine, a controlled trial as third line therapy in hypertension. Br J Clin Pharmacol 21: 621–626Google Scholar
  61. Cooperative Study Group (1987) Felodipine a new antagonist, as monotherapy in mild or moderate hypertension. Drugs 34 [suppl 3]: 139–148Google Scholar
  62. Cox JP, O’Boyle CA, Mee F, Kelly J, Atkins N, Coakley D, O’Brien ET (1988) The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurements. J Hum Hypertens 2: 41–47PubMedGoogle Scholar
  63. Crome P, Baksi A, Edwards J, Marley J (1989) Plasma nitrendipine concentrations in elderly normotensive volunteers after single and multiple dosing. Curr Med Res Opin 11: 279–282PubMedGoogle Scholar
  64. Culling W, Ruttley MSM, Sheridan DJ (1984) Acute haemodynamic effects of felodipine during betablockade in patients with coronary artery disease. Br Heart J 52: 431–434PubMedGoogle Scholar
  65. Czuczawar SJ, Chododkowska A, Kleinrok Z, Maek U, Jagie O, Wojtowicz E (1990) Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs. Eur J Pharmacol 176: 75–83Google Scholar
  66. Dagher E, Dumont L, Chartrand C (1989) Positive hemodynamic interaction between amrinone and diltiazem in anesthetized dogs. Can J Physiol Pharmacol 67: 1092–1097PubMedGoogle Scholar
  67. Damase-Michel C, Montastruc JL, Montastruc P (1989) Central cardiovascular actions of calcium channel antagonists in dogs. Fundam Clin Pharmacol 3 [suppl]: 57s - s64sPubMedGoogle Scholar
  68. Davidson RC, Bürsten SL, Keeley PA, Kenny MA, Stewart DK (1985) Oral nifedipine of the treatment of patients with severe hypertension. Am J Med 79 [suppl 4 A]: 26PubMedGoogle Scholar
  69. De Ponti F, D’Angelo L, Frigo GM, Crema A (1989) Inhibitory effects of calcium channel blockers on intestinal motility in the dog. Eur J Pharmacol 168: 133–144PubMedGoogle Scholar
  70. de Leeuw PW, Birkenhäger WH (1984) Effects of Verapamil in hypertensive patients. Acta Med Scand [suppl 681]: 125–128Google Scholar
  71. Deeg P, Weiss KH, Schmitz H (1987) Anti-ischemic effect of nisoldipine in patients with stable angina pectoris. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 244–247Google Scholar
  72. Denniss AR, Kingma JG, Hearse DJ, Downey JM, Yellon DM (1990) Long acting calcium antagonist anipamil limits myocardial necrosis and penetrates the ischemic zone during 24h of coronary artery oclusion in the dog. Can J Cardiol 6: 31–37PubMedGoogle Scholar
  73. DePover A, Matlib MA, Lee SW (1982) Specific binding of 3H-nitrendipine to membranes from coronary arteries and heart in relation to pharmacological effects: paradoxical stimulation by diltiazem. Biochem Biophys Res Commun 108: 110PubMedGoogle Scholar
  74. Diamond JR, Cheung JY, Fang LS (1984) Nifedipine-induced renal dysfunction. Alterations in hemodynamics. Am J Med 77: 905PubMedGoogle Scholar
  75. DiBona GF, Sawin LL (1984) Renal tubular site of action of felodipine. J Cardiovasc Pharmacol Exp Ther 228: 420–428Google Scholar
  76. DiPalma JR (1989) Nimodipine in subarachnoid hemorrhage. Am Fam Physician 40: 143–145PubMedGoogle Scholar
  77. Distler A, Fritschka E (1990) Hypertensive emergencies. In: Bühler FR, Laragh JH (eds) Handbook of hypertension, vol 13: The management of Hypertension. Elsevier, Amsterdam New York Oxford, pp 550–568Google Scholar
  78. Dodd MG, Machin I (1985) Antihypertensive effects of amlodipine a novel dihydropyridine calcium antagonist. Br J Pharmacol 85: 333 PGoogle Scholar
  79. Dow RJ, Graham DJM (1986) A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. Brit J Clin Pharmacol 22: 195s–202sGoogle Scholar
  80. Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M (1989) Pharmacokinetics of amlodipine in renal impairment. Eur J Clin Pharmacol 36: 205–208PubMedGoogle Scholar
  81. Drake-Holland AJ, Pugh S, Mills C, Noble MIM (1987) Does felodipine have a positive inotropic effect in the human? J Cardiovasc Pharmacol 10 [suppl 1]: S119–S120PubMedGoogle Scholar
  82. Dylewicz P, Kirch W, Santos SR, Hutt HJ, Moenig H, Ohnhaus EE (1987) Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 32: 563–568PubMedGoogle Scholar
  83. Ebata H, Mills JS, Nemcek K, Johnson JD (1990) Calcium binding to extracellular sites of skeletal muscle calcium channels regulates dihydropyridine binding. J Biol Chem 265: 177–182PubMedGoogle Scholar
  84. Echizen H, Eichelbaum M (1986) Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem. Clin Pharmacokinet 11: 425–449PubMedGoogle Scholar
  85. Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, Ronn O (1985 a) Felodipine kinetics in healthy men. Clin Pharmacol Ther 38: 205–211Google Scholar
  86. Edgar B, Hoffmann K-J, Lundborg P, Regardh C-G, Ronn O, Weidolf L (1985b) Absorption, distribution, and elimination of felodipine in man. Drugs 29 [suppl 2]: 9–15PubMedGoogle Scholar
  87. Edgar B, Bengtsson B, Elmfeldt D et al. (1985 c) Acute diuretic/natiuretic properties of felodipine in man. Drugs 29 [suppl 2]:176–184Google Scholar
  88. Edgar B, Regardh CG, Lundborg P, Romare S, Nyberg G, Ronn O (1987 a) Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm Drug Dispos 8: 235–248Google Scholar
  89. Edgar B, Collste P, Haglund K, Regardh CG (1987b) Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. Clin Invest Med 10: 388–394PubMedGoogle Scholar
  90. Eichelbaum M, Mikus G, Mast V, Fischer C, Kuhlmann U, Machleidt C (1988) Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. J Cardiovasc Pharmacol 12 [suppl 4]: S6–S10PubMedGoogle Scholar
  91. Eichelbaum M (1989) Pharmakokinetik und Metabolismus von Gallopamil. Z Kardiol 78 [suppl 5]: 20–24PubMedGoogle Scholar
  92. Elliott HL, Meredith PA, Reid JL, Faulkner JK (1988) A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol 12 [suppl 7]: S64–S66PubMedGoogle Scholar
  93. Elmfeldt D, Hedner T (1983) Felodipine - a new vasodilator, in addition to beta receptor blockade in hypertension. Eur J Clin Pharmacol 25: 571–575PubMedGoogle Scholar
  94. Ene MD, Roberts CJ (1987) Pharmacokinetics of nifedipine after oral administration in chronic liver disease. J Clin Pharmacol 27: 1001–1004PubMedGoogle Scholar
  95. Erdman R, Luttgau HC (1989) The effect of the phenylalkylamine D888 (devapamil) on force and calcium current in isolated frog skelettal muscle fibres. J Physiol (Lond) 413: 521–541Google Scholar
  96. Erne P, Bolli P, Bertel O, Hulthen L, Kiowski W, Muller FB, Biihler F (1983) Factors influencing the hypotensive effect of calcium antagonists. Hypertension 5 [suppl II]: 97–102Google Scholar
  97. Esper RJ, Esper RC, Baglivo HP, Castro JM, Rohwedder RW, Menna J (1984) Long-term effectiveness of nitrendipine in the treatment of mild to moderate arterial hypertension. J Cardiovasc Pharmacol 6 [suppl 7]: 1096 – 1099Google Scholar
  98. Etingin OR, Hajjar DP (1990) Calcium channel blockers enhance cholersteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circulat Res 66: 185–190PubMedGoogle Scholar
  99. Fadda GZ, Akmal M, Soliman AR, Lipson LG, Massry SG (1989) Correction of glucose intolerance and the impaired insulin release of chronic renal failure by verapamil. Kidney Int 36: 773–779PubMedGoogle Scholar
  100. Fagan TC, Brown R, Schnaper H, Smolens P, Montijo M, Michelson E (1989) Nicardipine and hydrochlorothiazide in essential hypertension. Clin Pharmacol Ther 45: 429–438PubMedGoogle Scholar
  101. Faulkner JK, McGibney D, Chasseud LF, Penny JL, Taylor JE (1986) Pharmacokinetics of amlodipine in healthy volunteers. Br J Clin Pharmacol 22: 21–26PubMedGoogle Scholar
  102. Fievet P, Boudjelal M, Demontis R, Fournier A (1989) Calcium antagonists and the kidney. Ann Intern Med 140: 637–643Google Scholar
  103. Finucci GF, Padrini R, Piovan D, Melica E, Merkel C, Gatta A, Zuin R (1989) Verapamil kinetics and liver function in patients with chronic cirrhosis. Int J Clin Pharmacol Res 8: 123–126Google Scholar
  104. Flamm ES (1989) The potential use of nicardipine in cerebrovascular disease. Am Heart J 117: 236–242PubMedGoogle Scholar
  105. Fleckenstein A (1983) Calciumantagonism in the heart and smooth muscle. Wiley, New York Chichester Brisbane Toronto Singapore, p 256Google Scholar
  106. Follath F, Taescher W (1988) Clinical Pharmacology of calcium antagonists. J Cardiovasc Pharmacol 12 [suppl 6]: 98–100Google Scholar
  107. Forette F, McClaran J, Hervy MP, Bouchacourt P, Henry JF (1989) Nicardipine in elderly patients with hypertension: a review of experience in France. Am Heart J 117: 256–261PubMedGoogle Scholar
  108. Franz IW, Wiewel D (1984) Antihypertensive effects on blood pressure at rest and during exercise of calcium antagonists, beta blockers, and their combination in antihypertensive patients. J Cardiovasc Pharmacol 6 [suppl 7]: 1037–1042Google Scholar
  109. Friedel HA, Sorkin EM (1988) Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 36: 682–731PubMedGoogle Scholar
  110. Frishman WH, Weinberg P, Peled HB, Kimmel B, Charlap S, Beer N (1984) Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis. Am J Med 77 [suppl 2B]: 35PubMedGoogle Scholar
  111. Fritschka E, Distler A, Götzen R, Thiede HM, Philipp Th (1984) Cross over comparison of nitrendipine and propranolol treatment in patients with essential hypertension. J Cardiovasc Pharmacol 6 [suppl 7]: 1100–1104Google Scholar
  112. Fritschka E, Kribben A, Distler A, Philip Th (1987) Inhibition of aggregation and calcium influx of human platelets by nitrendipine. J Cardiovasc Pharmacol 9 [suppl 4]: S85–S89Google Scholar
  113. Fu M, Hung JS, Yeh SJ, Lin FC, Hsu RS, Wu D (1987) Pharmacokinetics and pharmacodynamics effects of aequeous diltiazem in healthy humans. J Clin Pharmacol 27: 106–110PubMedGoogle Scholar
  114. Galizzi JP, Fosset M, Lazdunski M (1984) 3H-verapamil binding sites in skeletal muscle transverse tubule membranes. Biochem Biophys Res Commun 118: 239PubMedGoogle Scholar
  115. Ganguly A, Chiou S, Davis JS (1990) Intracellular mediators of potassium-induced aldosterone secretion. Life Sci 46: 173–180PubMedGoogle Scholar
  116. Gasser R (1990) Calcium antagonists: pharmacologic agents in search of new clinical indications. Angiology 41: 36–43PubMedGoogle Scholar
  117. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJA (1985) Efficacy of treatment with nimodipine (calcium antagonists) in patients with acute ischemic stroke; a placebo-controlled, double blind, randomized, multicenter trial. J Cereb Blood Flow Metab 5 [suppl 1]: S337–S338Google Scholar
  118. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJA (1988) A controlled trial of nimodipine in acute ischemic stroke. New Engl J Med 318: 203–207Google Scholar
  119. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York, pp 409–417Google Scholar
  120. Gibson RS (1989) Current status of calcium channel-blocking drugs after Q wave and non-Q wave myocardial infarction. Circulation 80 [suppl]: V107–V119Google Scholar
  121. Given BD, Lee TH, Stone PH, Dzau VJ (1985) Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. Arch Intern Med 145: 280Google Scholar
  122. Glasser SP, Chrysant SG, Graves J, Rofman B, Koehn DK (1989) Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. Am J Hypertension 2: 154–157Google Scholar
  123. Glasser SP, West TW (1988) Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Am J Cardiol 62: 518–522PubMedGoogle Scholar
  124. Glossmann H, Ferry DR (1983) Molecular approach to the calcium channel. In: Fleckenstein A, Hashimoto K, Herrmann M, Schwartz A, Seipel L (eds) New calcium antagonists: Recent developments and prospects. Gustav Fischer, Stuttgart New York, pp 63–98Google Scholar
  125. Glossmann H, Ferry DR, Göll A, Striessnig J, Schober M (1985) Calcium channels: basic properties as revealed by radioligand binding studies. J Cardiovasc Pharmacol 7 [suppl 6]: S20–S30PubMedGoogle Scholar
  126. Glossmann H, Ferry DR, Striessnig J, Göll A, Moosburger K, Schirmer M (1987) Interaction between calcium channel ligands and calcium channels. Circulat Res 61 [suppl 1]: 130–136Google Scholar
  127. Godfraind T, Egleme C, Finet M, Jaumin P (1987 a) The actions of nifedipine and nisoldipine on the contractile activity of human coronary nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxicol 61: 79–84Google Scholar
  128. Godfraind T, Egleme C, Finet M, Debande B, Jaumin P ( 1987 b) Comparison of nifedipine and nisoldipine on human arteries and human cardiac tissues in vitro. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 36–44Google Scholar
  129. Gould BA, Hornung RS, Mann S, Subramanian VB, Raftery EB (1983) Nifedipine or verapamil as sole treatment of hypertension. Hypertension 5 [suppl II]: 91–96Google Scholar
  130. Govoni S, Goss I, Di Giovine S, Battaini F, Trabucchi M (1990) Calcium antagonists inhibit metenkephalin immunoreactive material release: in vitro and ex vivo experiments. J Neural Transm Gen Sect 80: 1–8PubMedGoogle Scholar
  131. Graefe K-H, Ziegler R, Wingeder W, Rämsch K-D, Ahr G, Schmitz H (1987) Plasma level-effect relationships for some acute cardiovascular effects of nisoldipine and other dihydropyridine calcium channel antagonists. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 67–75Google Scholar
  132. Graziadei I, Zernig G, Grasseger A, Boer R, Schudt C, Glossmann H (1989) Hydrophobic calcium channel ligands: methodological problems and their solution. Am J Cardiol 64: 431–501Google Scholar
  133. Grech-Belanger O, Langlois S, LeBoeut E (1988) Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol 28: 477–480PubMedGoogle Scholar
  134. Greenberg B, Siemienczuk D, Broudy D (1987) Hemodynamic effects of PN 200–110 (Isradipine) in congestive heart failure. Am J Cardiol 59: 70B–74BPubMedGoogle Scholar
  135. Greenberger LM, Yang CP, Gindin E, Horwitz SB (1990) Photoaffinity probes for the alphal-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265: 4394–4401PubMedGoogle Scholar
  136. Grino JM, Sabate I, Castelao AM, Alsina J (1986) Influence of diltiazem on cyclosporine clearance. Lancet 1: 1387PubMedGoogle Scholar
  137. Grover GJ, Parham CS, Sleph PG, Moreland S (1989) Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765. J Pharmacol Exp Ther 251: 1020–1025PubMedGoogle Scholar
  138. Guazzi MD, DeCesare N, Galli C, Salvioni AS, Trumontana C, Tamborini GT, Bartorelli A (1984) Calcium channel blockade with nifedipine and angiotensine converting-enzyme inhibition with Captopril in the therapy of patients with severe hypertension. Circulation 70: 279PubMedGoogle Scholar
  139. Haas H, Härtfelder G (1962) Alpha-Isopropyl-alpha N-Methyl-N homoveratryl-alphaamino’ propyl 3,4-dimethoxyphenylaacetonitril, eine Substanz mit coronargefäßerweiternden Eigenschaften. Arzneimittelforschung 12: 549–558PubMedGoogle Scholar
  140. Haglund K, Collste P, Edgar B, Östman J (1985) Hypotensive effect of felodipine as monotherapy. Clin Invest Med 8: A131Google Scholar
  141. Hallen B, Guilbaud O, Stroemberg S, Lindeke B (1988 a) Single-dose pharmacokinetics of terodiline including a stable isotope technique for improvement of statistical evaluations. Biopharm Drug Dispos 9: 229–250Google Scholar
  142. Hallen B, Magnussen A, Bogentoft S, Ekelund P (1988b) Single- and multiple dose pharmacokinetics of terodiline in geriatric patients. Eur J Clin Pharmacol 34: 291–297PubMedGoogle Scholar
  143. Hansson L, Andren L, Öro L, Ryman T (1983) Pharmacokinetic and pharmacodynamic parameters in patients treated with nitrendipine. Hypertension 5 [suppl II]: 25–28Google Scholar
  144. Hanyok JJ, Chow MS, Kluger J, Izard MW (1988) An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. J Clin Pharmacol 28: 831–836PubMedGoogle Scholar
  145. Harrod CS (1987) Theophylline toxicity and nifedipine. Ann Intern Med 106: 480PubMedGoogle Scholar
  146. Hedner T, Elmfeldt D, Dahloef C, Sjoegren E (1987) Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. Drugs 34 [suppl 3]: 125–131PubMedGoogle Scholar
  147. Hedner T, Samuelsson O, Sjögren E, Elmfeldt D (1986) Treatment of essential hypertension with felodipine in combination with a diuretic. Eur J Clin Pharmacol 30: 133–139PubMedGoogle Scholar
  148. Heiss WD, Holthoff V, Pawlik G, Neveling M (1990) Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography. J Cereb Blood Flow Metab 10 (1): 127–132PubMedGoogle Scholar
  149. Held PH, Yusuf S, Furberg CD (1989) Calcium channel blockers in acute myocardial infarction and unstable angina: an overview: Br Med J 299: 1187–1192Google Scholar
  150. Hering S, Kleppisch T, Timin EN, Bodewei R (1989) Characterization of the calcium channel state transitions induced by the enantiomers of the 1,4-dihydropyridine Sandoz 202 791 in neonatal rat heart cells. A nonmodulating receptor model. Pflügers Arch 414: 690–700PubMedGoogle Scholar
  151. Herlitz H, Aurell M, Rjorck S, Granerus G (1984) Renal effects of felodipine in hypertensive patients with reduced renal function. Drugs 29 [suppl 2]: 192Google Scholar
  152. Hermsmeyer K, Rusch NJ (1987) Felodipine actions on vascular smooth muscle Ca2+ channels. J Cardiovasc Pharmacol 10 [suppl 1]: S40–S43PubMedGoogle Scholar
  153. Hertz F, Cloarec A (1989) Comparative antiulcer and antisecretory effects of various calcium antagonists. Gen Pharmacol 20: 635–640PubMedGoogle Scholar
  154. Hinderling PH, Eckert M, Gasic S, Eichler HG, Potzi R et al. (1986) Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis. Eur J Clin Pharmacol 31: 397–404PubMedGoogle Scholar
  155. Hirth et al. C, Federmann A, Garthoff B, Hertie L, Kazda S, Stasch JP (1987) The effect of nisoldipine in experimentally induced renal failure. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 144–150Google Scholar
  156. Hla KK, Henry JA, Latham AN (1987) Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol 24: 661–664PubMedGoogle Scholar
  157. Hoeglund P, Nilsson LG (1988) Physiological disposition of intravenously administered Relabeled diltiazem in healthy volunteers. Ther Drug Monit 10: 401–409Google Scholar
  158. Hof RP, Vuorela HJ, Neumann P (1982) PY 108–068, a new potent, and selective inhibitor of calcium-induced contraction of rabbit aortic rings. J Cardiovasc Pharmacol 4: 344–351PubMedGoogle Scholar
  159. Hof RP, Hof A, Scholtysik G, Menninger K (1984a) Effects of the new calcium antagonist PN 200-110 on the myocardium and the regional peripheral circulation in the anesthetized cats and dogs. J Cardiovasc Pharmacol 6: 407–416PubMedGoogle Scholar
  160. Hof RP (1984 b) The calcium antagonist PY 108–068 and verapamil diminish the effects of angiotensin II: Sites of interaction in the peripheral circulation of anesthetized cats. Br J Pharmacol 82: 51–60Google Scholar
  161. Hof RP, Hof A, Rüegg UT, Cook NS, Vogel A (1986) Stereoselectivity at the calcium channel: different profiles of haemodynamic activity of the enantiomers of the dihydropyridine derivative PN 200-110. J Cardiovasc Pharmacol 8: 221–226PubMedGoogle Scholar
  162. Hof RP, Salzmann R, Siegl H (1987) Selective effects of PN 200–110 (Isradipine) on the peripheral circulation and the heart. Am J Cardiol 59: 30B–36BPubMedGoogle Scholar
  163. Hof RP, Hof A (1988) The renin-angiotensin system modulates the peripheral vascular effects of the calcium antagonist isradipine in anesthetized rabbits. J Cardiovasc Pharmacol 12: 233–238PubMedGoogle Scholar
  164. Hofman J, Siergiejko Z, Chyrek-Borowska S (1990) The influence of the calcium channel antagonist verapamil on histamine release from target cells. Arch Immunol Ther Exp (Warsz) 37: 55–59Google Scholar
  165. Horvath G, Benedek G, Szikszay M (1990) Enhancement of fentanyl analgesia by Clonidine plus verapamil in rats. Anesth Anaig 70: 284–288Google Scholar
  166. Hosono M, Taira N (1987) Coronary vasodilator versus cardiac effects of MCI-176, a novel quinazolinone calcium antagonist, in the dog heart. J Cardiovasc Pharmacol 9: 633–640PubMedGoogle Scholar
  167. Hughes GS Jr, Cowart TD, Oexmann MJ, Conradi EC (1988) Verapamil-induced natriuretic and diuretic effects: dependency on sodium intake. Clin Pharmacol Ther 44: 400–407PubMedGoogle Scholar
  168. Hulthen UL, Kathman PL (1988) Renal effects of acute and long-term treatment with felodipine in essential hypertension. J Hypertens 6: 231–237PubMedGoogle Scholar
  169. Ikeda M et al. (in press) Clinical usefulness of nilvadipine on essential hypertension. A multi-center cooperative double-blind group-comparative study with nicardipine hydrochloride. Igaku No AyumiGoogle Scholar
  170. Iliopoulou A, Turner P, Warrington SJ (1983) Acute hemodynamic effects of a new calcium antagonist, nicardipine, in man, a comparison with nifedipine. Br J Clin Pharmacol 15: 59PubMedGoogle Scholar
  171. Inouye IK, Massie BM, Benowitz N, Simpson P, Loge D (1984) Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide. Am J Cardiol 53: 1588PubMedGoogle Scholar
  172. Ishii M et al. (1986) The usefulness of FK 235 on essential hypertension. A multi-center open trial by administration with FK 235 and FK 235 plus hypotensive diuretics. Jap J Clin Med 63: 2017–2030Google Scholar
  173. Ishii A (1989) Inhibiton of 3H-nitrendipine-binding in rat aortic and cerebral cortex membranes by the new dihydropyridine calcium antagonist benidipine hydrochloride. Arzneimittelforschung 39: 1546–1550PubMedGoogle Scholar
  174. Iwanami M, Shibanuma T, Fujimoto M, Kawai R, Tamazawa K, Takenaka T, Takahashi K, Murakami M (1979) Synthesis of new watersoluble dihydropyridine vasodilators. Chem Pharm Bull (Tokyo) 27: 1426Google Scholar
  175. Jackson B, Morgan TO, Gibson J, Anderson A (1987) Felodipin vs Prazosin as an addition to a betablocker in the treatment of essential hypertension. The Australian Multicenter Study. Drugs 34 [suppl 3]: 109–119PubMedGoogle Scholar
  176. Johnson JD, Andrews CT, Khabbaza EJ, Mills JS (1987) The interaction of felodipine with calcium-binding proteins. J Cardiovasc Pharmacol 10 [suppl 1]: S53–S59PubMedGoogle Scholar
  177. Jones CR, Rae AP, Been M (1985) Electrophysiological effects of felodipine in combination with metroprolol. Drugs 29 [suppl 2]: 81–86PubMedGoogle Scholar
  178. Jorgensen NP, Walstad RA (1988) Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. Pharmacol Toxicol 63: 105–107PubMedGoogle Scholar
  179. Juneja R, Gupta I, Wali A, Sanyal SN, Chakravarti RN, Majumdar S (1990) Effects on verapamil of different spermatozoal functions in guinea pigs - a preliminary study. Contraception 41: 179–187PubMedGoogle Scholar
  180. Kageyma M, Matsumura Y, Hayashi K, Hosokowa T, Morimoto S (1990) Inhibitory effects of nisoldipine and saralasin on angiotensin II-induced antidiuresis in anaestetized dogs. Jpn J Pharmacol 52: 245–253Google Scholar
  181. Kajiwara N et al. (1985) Effect of FK 235 on diurnal variation of blood pressure in patients with essential hypertension. Jpn J Clin Exp Med 62: 209–218Google Scholar
  182. Kann J, Krol GJ, Raemsch KD, Burkholder DE, Levitt MJ (1984) Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol 6 [suppl 7]: S968–S973PubMedGoogle Scholar
  183. Katzman PL, Hulthen UL, Hökfelt B (1986) The effects of eight weeks treatment with the calcium antagonist felodipine on blood pressure heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. Br J Clin Pharmacol 21: 633–640PubMedGoogle Scholar
  184. Kauker ML, Zeigler DW, Zawada ET (1987) Renal tubular effects of nisoldipine, a calcium channel blocker, in rats. J Cardiovasc Pharmacol 9 [suppl 1]: S32–S38PubMedGoogle Scholar
  185. Kawakami M, Bian K, Toda N (1989) Vasodilator actions of felodipine, a new calcium entry blocker. Nippon Yakurigaku Zasshi 94: 251–256PubMedGoogle Scholar
  186. Kazda S, Hoffmeister F (1979) Effect of some cerebral vasodilators on the postischemic impaired cerebral reperfusion in cats. Naunyn Schmiedebergs Arch Pharmacol 307 [suppl]: R43Google Scholar
  187. Kazda S, Garthoff B, Meyer H, Schloßmann K, Stoepel K, Towart R, Vater W, Wehinger E (1980) Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4 dihydro- 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylate (nisoldipine, Bay K 5552). Arzneimittelforschung (Drug Res) 30: 2144–2162Google Scholar
  188. Kazda S, Stasch J-P, Hirth C (1987) Experimental pharmacology of nisoldipine: perspectives from long-term studies In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 3–12Google Scholar
  189. Keech AC, Harper RW, Harrison PM, Pitt A, MacLean AJ (1988) Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man. Eur J Clin Pharmacol 35: 363–366PubMedGoogle Scholar
  190. Kern MJ (1989) Influence of calcium channel antagonist therapy on the ischemic response to acute coronary occlusion in humans. Clin Cardiol 12 [suppl 3]:III77–III85PubMedGoogle Scholar
  191. Kingma PJ, Simons JP, Nieuwenhuijen Kruseman AC, Wolffenbuttel BH (1990) Calcium entry blockers and their effects on glucose metabolism. Neth J Med 36: 32–38PubMedGoogle Scholar
  192. Kiowski W, Bertel O, Erne P et al. (1983) Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension 5 [suppl I]: 70–74Google Scholar
  193. Kirch W, Hütt HJ, Heidemann H, Rämsch K, Janisch HD, Ohnhaus EE (1984) Drug interactions with nitrendipine. J Cardiovasc Pharmacol 6 [suppl 7]: 982–985Google Scholar
  194. Kirch W, Kleinbloesem CH, Beiz GG (1990) Drug interactions with calciumantagonists. Pharmacol Ther 45: 109–136PubMedGoogle Scholar
  195. Kishida H, Toyam S, Yanaga T, Suzuki K (1988) Effect of a new calcium antagonist, nilvadipine, on variant angina pectoris evaluated by 24-hour Holter electrocardiography. Jpn Heart J 29: 781–793PubMedGoogle Scholar
  196. Kiue A, Sano T, Suzuki K, Inada H, Okumura M, Kikuchi J, Sato S, Kohno K, Kuwano M (1990) Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res 50: 310–317PubMedGoogle Scholar
  197. Klein W, Brandt D, Vrecko K. Härringer M (1983) Role of calcium antagonists in the treatment of essential hypertension. Circulat Res 52 [suppl I]: 174–181Google Scholar
  198. Knorr A, Kazda S, Garthoff B, Stasch JP, Towart R (1986) Akute und chronische Wirkung von Nitrendipin bei experimentellem Hochdruck: In: Distler A (Hrsg) Kalziumantagonisten in der Hochdrucktherapie. Schattauer, Stuttgart New York, S 27–33Google Scholar
  199. Krishna GG, Narins RG (1989) Calcium channel blockers. Progression of renal disease. Circulation 80 [suppl]:IV47–IV51PubMedGoogle Scholar
  200. Kroemer IX (1986) Kalziumantagonisten erhöhen Neurotoxizität von Carpamazepin. Arzneimitteltherapie 4: 163–164Google Scholar
  201. Kuramoto K (1989) Double-blind studies of calcium antagonists in the treatment of hypertension in Japan. J Cardiovasc Pharmacol 13 [suppl 1]: S29–S35PubMedGoogle Scholar
  202. Laher MS, Kelly JG, Doyle GD, Carmody M, Donohoe JF, Greb H, Volz M (1988) Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 12 [suppl 7]: S60–S63PubMedGoogle Scholar
  203. Landahl S, Edgar B, Gabriellson M, Larson M, Lemfelt B, Lundborg P, Regärdh CG (1988) Pharmacokinetics of felodipine in elderly hypertensive patients - a comparison with young healthy subjects. Clin Pharmacokinet 14: 374–383PubMedGoogle Scholar
  204. Langley MS, Sorkin EM (1989) Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential incerebrovascular disease. Drugs 37: 669–699PubMedGoogle Scholar
  205. Lasseter KC, Shamblen EC, Murdoch AA, Burkholder DE, Krol GJ, Taylor RJ, Vanov SK (1984) Steady state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol 6 [suppl 7]: S977–S981PubMedGoogle Scholar
  206. Lederballe Pederson O, Christensen CK, Mikkelson E et al. (1980) Relationship between the antihypertensive effect and steady state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol 18: 287–293Google Scholar
  207. Lederballe-Pederson O (1981 a) Calcium blockade in arterial hypertension. Hypertension 5 [suppl II]:74–79Google Scholar
  208. Lederballe Pederson O (1981b) Calcium blockade as a therapeutic principle in arterial hypertension. Acta Pharmacol Toxicol [suppl II]49: 1–31Google Scholar
  209. Lee SM, Williams R, Warnock D, Emmett M, Wolbach RA (1986) The effects of nicardipine in hypertensive subjects with impaired renal function. Br J Clin Pharmacol 22: 2Google Scholar
  210. Lehmann HU, Taegener-Torge C, Witt E, Beck OA, Hochrein H (1979) Wirkungsvergleich zwischen Gallopamil (D 600) und Verapamil. Angiocardiology 2: 103–107Google Scholar
  211. Leonetti G, Sala C, Bianchetti C, Terzoli L, Zanchetti A (1980) Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol 18: 375–382PubMedGoogle Scholar
  212. Leonetti G, Cuspidi C, Sampieri L, Terzoli L, Zanchetti A (1982) Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 4: S319–S324PubMedGoogle Scholar
  213. Leonetti G, Gradnik R, Terzoli L, Fruscio M, Rupoli L, Zanchetti A (1984) Felodipine a new vasodilating drug: blood pressure, cardiac, renal, and humoral effects in hypertensive patients. J Cardiovasc Pharmacol 6: 392–398PubMedGoogle Scholar
  214. Leonetti G, Gradnik R, Terzoli L et al. (1986) Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients. J Cardiovasc Pharmacol 8: 1243–1248PubMedGoogle Scholar
  215. Leonetti G (1987) Antihypertensive efficacy of nicardipine, in monotherapy and assossiation, in mild or moderate hypertensives with and without concomitant disease: interim report of italian multicentre study. J Hypertension 5 [suppl. 5]: S575–S577Google Scholar
  216. Leonetti G, Zanchetti A (1988) Antihypertensive efficacy of nicardipine-based treatment in patients of different age and in patients with isolated systolic hypertension. J Hypertens 6 [suppl 4]: S655–S657Google Scholar
  217. Lessem J, Bellinetto A (1983) Interaction between digoxin and the calcium antagonists nicardipine and tiapamil. Clin Ther 5: 595–602PubMedGoogle Scholar
  218. Lettieri JT, Krol GJ, Yeh SC, Burkholder DE, Zinny M, O’Donnell D (1988) The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 12 [suppl 4]: S129–S132PubMedGoogle Scholar
  219. Levine MA, Ogilvie RI, Leenen FH (1988) Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin Pharmacol Ther 43: 39–48PubMedGoogle Scholar
  220. Levy MN (1989) Role of calcium in arrhythmogenesis. Circulation 80 [suppl]:IV23–IV30PubMedGoogle Scholar
  221. Lewis GRJ, Morley KD, Lewis BM, Bones PJ (1978) The treatment of hypertension with verapamil. NZ Med J 612: 351–354Google Scholar
  222. Lindholm A, Henricsson S (1987) Verapamil inhibits cyclosporine metabolism. Lancet 1: 1262–1263PubMedGoogle Scholar
  223. Littleton JM, Little HJ, Whittington MA (1990) Effects of dihydropyridine calcium channel antagonists in ethanol withdrawal; doses required, stereospecificity and actions of Bay K 8644. Psychopharmacology (Berl) 100: 387–392Google Scholar
  224. Ljung B (1985) Vascular selectivity of felodipine. Drugs 29 [suppl 2]: 46–58PubMedGoogle Scholar
  225. Ljung B, Kjellstedt A, Orebäck B (1987) Vascular versus myocardial selectivity of calcium antagonists studied by concentration-time-effect relations. J Cardiovasc Pharmacol 10 [suppl 1]:S34–S39 und S96PubMedGoogle Scholar
  226. Lund-Johansen P (1985) Hemodynamic effects of calcium channel blockers at rest and during exercise in essential hypertension. Am J Med 79 [suppl 4A]: 11PubMedGoogle Scholar
  227. Lund-Johansen P, Omvik P (1987) Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension. J Cardiovasc Pharmacol 10 [suppl 1]: S139–S148PubMedGoogle Scholar
  228. MacLeod BA, Moult M, Saint KM, Walker MJ (1989) The antiarrhythmic efficacy of intravenous anipamil against occlusion and reperfusion arrhythmias. Br J Pharmacol 98: 1165–1172PubMedGoogle Scholar
  229. MacLeod D, Wathen CG, Tucker L, Forret E, Hill K, Muir AL (1985) Felodipin can replace minoxidil in the treatment of refractory hypertension. J Hypertens 3 [suppl 3]: 469–470Google Scholar
  230. MacMahon FG, Vargas R, Ryan JR, Miller H, Faraday S (1988) An acute dose-response pharmacodynamic evaluation of orally administered isradipine (PN-200-110) in hypertensive patients. J Clin Pharmacol 28: 664Google Scholar
  231. MacNally P, Mistry N, Idle J, Walls J, Feehally J (1989) Calcium channel blockers and cyclosporine metabolism. Transplantation 48: 1071Google Scholar
  232. Magometschnigg D (1983) Acute hypotensive response to nifedipine. Hypertension 5 [suppl II]: 80–84Google Scholar
  233. Maier-Lenz H, Rode H, Lenau H, Thieme G, Woelke E, Kobayashi H, Kobayashi S, Oka T (1988) Benidipine hydrochloride - a new calcium channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension. Arzneimittelforschung 38: 1757–1763PubMedGoogle Scholar
  234. Maisel AS, Motulsky HJ, Insel PA (1985) Hypotension after quinidine plus verapamil. Possible additive competition at alpha-adrenergic receptors. N Engl J Med 312: 167–170PubMedGoogle Scholar
  235. Malinowski R, Wasek Z, Frank-Piskorska A (1989) Evaluation of the protektive effects of nifedipine and verapamil in patients with bronchial hyperreactivity. Wiad Lek 42: 129–133PubMedGoogle Scholar
  236. Marthan R, Woolcock AJ (1989) Is a myogenic response involved in deep inspiration-induced bronchoconstriction in athmatics? Am Rev Respir Dis 140: 1354–1358PubMedGoogle Scholar
  237. Mason RP, Campbell SF, Wang SD, Herbette LG (1989) Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 36: 634–640PubMedGoogle Scholar
  238. Matlib MA (1989) Relaxation of potassium chloride-induced contractions by amlodipine and its interaction with the 1,4-dihydropyridine-binding site in pig coronary artery. Am J Cardiol 64: 511–571Google Scholar
  239. Mauser M, Voelker W, Ickrath O, Karsch KR (1989) Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockade in coronary artery disease. Am J Cardiol 63 (1): 40–44PubMedGoogle Scholar
  240. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS (1989) Mechanism of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem Pharmacol 38: 3611–3619PubMedGoogle Scholar
  241. McLeay RAB, Stallard TJ, Watson RDS et al. (1983) The effect of nifedipine on arterial pressure and reflex cardiac control. Circulation 67: 1084–1090PubMedGoogle Scholar
  242. McPhee GJA, Mclnnes GT, Thompson GG, Brodie MJ (1986) Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1: 700–703Google Scholar
  243. Meredith PA, Elliott HL, Reid JL (1988) The clinical pharmacology of nisoldipine: studies on the pharmacokinetics and interactions with betablockers. In: Lichtlen RR, Hugenholtz PG (eds) Nisoldipine 1988. Schattauer, Stuttgart New York, pp 12–21Google Scholar
  244. Meyer FB, Anderson RE, Sundt TM Jr (1990) Anticonvulsant effects of dihydropyridine calcium antagonists in electrocortical shock seizures. Epilepsia 31: 68–74PubMedGoogle Scholar
  245. Mikus G, Fischer C, Heuer B, Langen C, Eichelbaum M (1987) Application of a stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. Br J Clin Pharmacol 24: 561–569PubMedGoogle Scholar
  246. Mildenberger D, Klepzig H Jr, Hopf R, Kaltenbach M (1989) Nebenwirkungsspektrum von Gallopamil im Vergleich zu anderen Calciumantagonisten. Z Kardiol 78 [suppl 5]: 25–28PubMedGoogle Scholar
  247. Mitchell KD, Navar LG (1990) Tubuloglomerular feedback responses during peritubular infusions of calcium channel blockers. Am J Physiol 258: F537–F544PubMedGoogle Scholar
  248. Mizuno K et al. (1986) Antihypertensive effect of a new calcium channel blocker, FK 235, in essential hypertension. Chem Pathol Pharmacol 52: 3–15Google Scholar
  249. Mooser V, Waeber B, Nussberger J, Brunner HR (1988) Antihypertensive effect of diltiazem administered once and twice daily. J Hum Hypertens 2: 257–260PubMedGoogle Scholar
  250. Morimoto S, Ohyama T, Hisaki K, Matsumura Y (1989) Effects of CV-4093, a new dihydropyridine calcium channel blocker, on renal hemodynamics and function in stroke-prone spontaneously hypertensive rats ( SHRSP ). Jpn J Pharmacol 51: 257–265PubMedGoogle Scholar
  251. Morris MJ, David-Dufilho M, Devynck MA (1988) Red blood cell ionized calcium concentration in spontaneous hypertension: modulation in vivo by the calcium antagonist PN 200.110. Clin Exp Pharmacol Physiol 15: 257–260PubMedGoogle Scholar
  252. Motomura S, Hashimotot K (1990) Reconsideration of vascular selectivity of dihydropyridine calcium antagonists: comparison of cardiovascular profile of mepirodipine, a novel dihydropyridine, consisting of a single stereoisomer with (+)-(S)-(S) conformation, with those of nifedipine and nicardipine. Jpn J Pharmacol 52: 319–330PubMedGoogle Scholar
  253. Muiesan G, Agabiti-Rosei, Castellano M, Alicandri CL, Corea L, Fariello R, Beschi M, Romanelli G (1982) Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension. J Cardiovasc Pharmacol 4: S325–S329PubMedGoogle Scholar
  254. Muir AL, Wathen CG, Hannan WJ (1985) Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension. Drugs 29 [suppl 2]: 59–65PubMedGoogle Scholar
  255. Müller FB, Bolli P, Erne P, Block LH, Kiowski W, Bühler FR (1984) Antihypertensive therapy with the long acting calcium antagonist nitrendipine. J Cardiovasc Pharmacol 6 [suppl 7]: 1073–1076Google Scholar
  256. Müller-Schweinitzer E, Neumann P (1983) In vitro effects of the calcium antagonists PN 200–110, nifedipine, and nimodipine on human and canine cerebral arteries. J Cereb Blood Flow Metab 3: 354–361PubMedGoogle Scholar
  257. Murphy BJ, Rogers CA, Sunahara RK, Lemaire S, Tuana BS (1990) Identification, characterization, and photoaffinity labeling of the dihydropyridine receptor associated with the L-type calcium channel from bovine adrenal medulla. Mol Pharmacol 37: 173–181PubMedGoogle Scholar
  258. Murphy MB, Bulpitt CJ, Dollery CT (1984) Role of nifedipine in the treatment of resistant hypertension. Am J Med 77 [suppl 2B]: 16PubMedGoogle Scholar
  259. Nafziger AN, May JJ, Bertino JB (1987) Inhibition of theophylline elimination by diltiazem therapy. J Clin Pharmacol 27: 862–865PubMedGoogle Scholar
  260. Nagaoka A, Shibota M, Hamajo K (1989 a) Effects of a new dihydropyridine derivative, CV- 4093.2HC1, on renal hemodynamics in spontaneously hypertensive rats. Jpn J Pharmacol 51: 25–35Google Scholar
  261. Nagaoka A, Shibota M (1989b) Natriuretic action of manidipine hydrochloride, a new calcium channel blocker, in spontaneously hypertensive rats. Jpn J Pharmacol 51: 299–301PubMedGoogle Scholar
  262. Nayler WG (1990) Kalziumantagonisten. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  263. Nayler WG, Panagiotopoulos S, Sturrock WJ (1987) Effect prolonged treatment with nisoldipine on cholesterol deposition and cardiac noradrenaline reserves: a comparative study. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 3–12Google Scholar
  264. Ninomiya M, Tani T, Nakajima S, Ueda M (1989) Effects of S-312, a new calcium antagonist, on the mechanical and electrophysiological responses of isolated cardiovascular preparations. Jpn J Pharmacol 51: 227–238PubMedGoogle Scholar
  265. Niwa T, Tokuma Y, Noguchi H (1987) Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog. Res Commun Chem Pathol Pharmacol 55: 75–88PubMedGoogle Scholar
  266. Nomura M, Kimura Y, Yoshida M, Satoh S (1989) Antihypertensive effect of a new dihydropyridine calcium entry blocker in conscious hypertensive and normotensive rats. Arzneimittelforschung 39: 1542–1545PubMedGoogle Scholar
  267. Ogilvie RI (1985) Effect of nifedipine and propranolol on blood flow, venous compliance and blood pressure in essential hypertension. Can Med Ass J 132: 1137PubMedGoogle Scholar
  268. Ohkura T et al. (1986) Antihypertensive effect and safety of nilvadipine in patients with renal parenchymal hypertension. J Clin Ther (Rinsho-Iyaku) 2: 1507–1515Google Scholar
  269. Ohtsuka M, Ono T, Hiroi J, Esumi K, Kikuchi H, Kurthada S (1983) Comparison of the cardiovascular effects of FR34235, a new dihydropyridine, with other calcium antagonists, J Cardiovasc Pharmacol 5: 1074–1082PubMedGoogle Scholar
  270. Ohtsuka M, Sakai S, Miura S, Kurosaki M, Koibuchi Y, Ono T, Shibayama F (1989a) Effects of nilvadipine, a new calcium entry blocker, on systemic blood pressure, cardiac hypertrophy and venous distensibility in spontaneously hypertensive rats. Arch Int Pharmacodyn Ther 301: 228–245PubMedGoogle Scholar
  271. Ohtsuka M, Yokota M, Kodama I, Yamada K, Shibata S (1989b) New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype. Gen Pharmacol 20: 539–556PubMedGoogle Scholar
  272. Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (1989) Antihypertensive effect of CS-905, a novel dihydropyridine calcium channel blocker. Jpn J Pharmacol 51: 57–64PubMedGoogle Scholar
  273. Olivari MT, Bartorelli C, Polese A et al. (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59: 1056–1062PubMedGoogle Scholar
  274. Onoda JM, Nelson KK, Pilarski SM, White NS, Mihu RG, Honn KV (1990) Combination chemotherapy with cisplatin and nifedipine: synergistic antitumor effects against a cisplatin-resistant subline of the B 16 amelanotic melanoma. Clin Exp Metastasis 8: 59–73PubMedGoogle Scholar
  275. Palmi M, Sgaragli G (1989) Hyperthermia induced in rabbits by organic calcium antagonists. Pharmacol Biochem Behav 34: 325–330PubMedGoogle Scholar
  276. Pan M, Janis RA, Triggle DJ (1983) Comparison of the equilibrium and kinetic binding characteristics of tritiated Ca2+ channel inhibitors, nisoldipine, nimodipine, nitrendipine and nifedipine. Pharmacologist 25:202, abstr. 257Google Scholar
  277. Payen D, Lamer C, Raggueneau JL (1989) Calcium inhibitors: effect on cerebral blood flow and intracranial pressure. Agressologie 30: 408–410PubMedGoogle Scholar
  278. Penny WJ, Lewis MJ (1989) Nifedipine is excreted in human milk. Eur J Clin Pharmacol 36: 427–428PubMedGoogle Scholar
  279. Perna AF, Smogorzewski M, Massry SG (1989) Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int 36: 453–457PubMedGoogle Scholar
  280. Petho A, Neumann T, Vetterlein F, Schmidt G (1989) Influence of diltiazem on postischemic microcirculation and function in the rat kidney. Microvasc Res 38: 223–236PubMedGoogle Scholar
  281. Pochet JM, Pirson Y (1986) Cyclosporine-diltiazem interaction. Lancet 11: 460Google Scholar
  282. Rahn KH, Mooy J, Böhm R, Vet AVD (1985) Reduction of bioavailability of verapamil by rifampin. N Engl J Med 312: 920–921PubMedGoogle Scholar
  283. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM (1990) Photosensitized labeling of a functional multitransporter in living drug-resistant tumor cells. J Biol Chem 265: 3975–3980PubMedGoogle Scholar
  284. Regärdh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky CW (1989) Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 36: 473–479PubMedGoogle Scholar
  285. Rehnqvist N, Billing E, Moberg L, Lundman T, Olsson G (1987) Pharmacokinetics of felodipine and effect on digoxin plasma-levels in patients with heart failure. Drugs 34 [suppl 3]: 33–42PubMedGoogle Scholar
  286. Reid JL, Meredith PA, Donnelly R, Elliott HL (1988) Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol 12 [suppl 7]: S22–S26PubMedGoogle Scholar
  287. Resnick LM, Nicholson JP, Laragh JH (1989) The effects of calcium channel blockade on blood pressure and calcium metabolism. Am J Hypertens 2: 927–930PubMedGoogle Scholar
  288. Robertson DR, Waller DG, Renwick AG, George CF (1988) Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 25: 297–305PubMedGoogle Scholar
  289. Rönn O, Bengtsson B, Edgar B, Raner S (1985) Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol. Drugs 29 [suppl 2]: 16–25PubMedGoogle Scholar
  290. Rosing DR, Epstein SE (1982) Verapamil in the treatment of hypertrophic cardiomyopathy. Ann Intern Med 96: 670–672PubMedGoogle Scholar
  291. Roy LF, East DS, Browning FM, Shaw D, Ogilvie RI, Cardella C, Leenen FH (1989) Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart- transplant and kidney-transplant patients. Clin Pharmacol Ther 46: 657–667PubMedGoogle Scholar
  292. Rudin M, Sauter A (1989) Dihydropyridine calcium antagonists reduce the consumption of high-energy phosphates in the rat brain. A study using combined 31P/1H magnetic resonance spectroscopy and 31P saturation transfer. J Pharmacol Exp Ther 251: 700–706PubMedGoogle Scholar
  293. Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ et al. (1986) The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica 16: 341–349PubMedGoogle Scholar
  294. Saida K, van Breemen C (1984) Characteristics of the norepinephrine-sensitive calcium-store in vascular smooth muscle. Blood Vessels 21: 43–46PubMedGoogle Scholar
  295. Sato H, Ikenouchi H, Aoyagi T, Matsui H, Mochizuki T, Momomura S-I, Serizawa T, Iizuka M, Sugimoto T (1990) Acute hemodynamic effects of nilvadipine, a new calcium channel blocker, in patients with congestive heart failure. J Cardiovasc Pharmacol 15: 317–322PubMedGoogle Scholar
  296. Sato M, Nagao T, Yamaguchi I, Najajima H, Kiyomoto A (1971) Pharmacological studies on a new 1,5-benzothiazepine derivate (CDR-401) I. Cardiovascular actions. Arzneimittelforschung 21: 1338–1343PubMedGoogle Scholar
  297. Satoh P et al. (1986) Influence of nilvadipine (FK 235) on serum digoxin concentration in patients with congestive heart failure. Jpn Pharmacol Ther (Yakuri-To-Chyrio) 14: 7387–7394Google Scholar
  298. Scherling D, Ahr G, Karl W (1987) Biotransformation of nisoldipine in man. In: Hugenholtz PG, Meyer J (eds) Nisoldipine 1987. Springer, Berlin Heidelberg New York Tokyo, pp 85–88Google Scholar
  299. Schwartz A, McKenna E, Vaghy PL (1988) Receptors for calcium antagonists. Am J Cardiol 62: 3G–6GPubMedGoogle Scholar
  300. Schwartz JB (1988) Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. J Cardiovasc Pharmacol 12: 1–5PubMedGoogle Scholar
  301. Scriabine A, Kazda S (1989) Pharmacological basis for use of calcium antagonists in hypertension. Magnesium 8: 253–265PubMedGoogle Scholar
  302. Sengelv H, Winther K (1989) Effect of felodipine, a new calcium channel antagonist, on platelet function and fibrinolytic activity at rest and during exercise. Eur J Clin Pharmacol 37: 453–457Google Scholar
  303. Shultz PJ, Raij L (1990) Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 15 [suppl 2]: 176–180Google Scholar
  304. Silke B, Verma SP, Frais MA, Reynolds G, Jackson N, Taylor SH (1985) Haemodynamic analysis of the effects of nicardipine and metoprolol alone and in combination in coronary artery disease. Eur Heart J 6: 930–938PubMedGoogle Scholar
  305. Silverman M, Rose H, Puschett JB (1989) Modifications in proximal tubular function induced by nitrendipine in a rat model of acute ischemic renal failure. J Cardiovasc Pharmacol 14:799–802 Silvestroni L, Menditto A (1989) Calcium uptake in human spermatozoa: characterization and mechanisms. Arch Androl 23: 87–96Google Scholar
  306. Singh BN, Opie LH (1984) Calcium antagonists. In: Opie LH (ed) Drugs for the heart. Grune & Stratton, London, p 39Google Scholar
  307. Singh BN, Josephson MA (1990) Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine. Am Heart J 119: P427–P434Google Scholar
  308. Snyder SH, Reynolds IJ (1985) Calcium-antagonist drugs: receptor interactions that clarify therapeutic effects. N Engl J Med 313: 995PubMedGoogle Scholar
  309. Sokol PP, Huiatt KR, Holohan PD, Ross CR (1989) Gentamicin and verapamil compete for a common transport mechanism in renal brush border membrane vesicles. J Pharmacol Exp Ther 251: 937–942PubMedGoogle Scholar
  310. Soons PA, de Boer AG, van Brummelen P, Breimer DD (1989) Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. Br J Clin Pharmacol 27: 179–189PubMedGoogle Scholar
  311. Spence JD (1989) Pathogenesis of atherosclerosis and its complications: effects of antihypertensive drugs. J Hum Hypertens 3 [suppl 2]: 63–68PubMedGoogle Scholar
  312. Staneva-Stoytcheva D, Popova J, Mutafova-Yambolieva V, Alov P (1990) Influence of long-term treatment with the calcium-antagonists nifedipine, verapamil, flunarizine and with the calmodulin antagonist trifluoperazine on beta-adrenenoceptors in rat cerebral cortex. Gen Pharmacol 21: 149–152PubMedGoogle Scholar
  313. Stjarne L, Msghina M, Stjarne E (1990) K+ and Ca2+-channel blocking agents increase or decrease stimulus evoked but not spontaneous quantal transmitter release in sympathetic nerve terminals. Acta Physiol Scand 138: 235–237PubMedGoogle Scholar
  314. Stoepel K, Heise A, Kazda S (1981) Pharmacological studies on the antihypertensive effect of nitrendipine. Arzneimittelforschung (Drug Res) 31: 2056–2061Google Scholar
  315. Stone PH, Antman EM, Müller JE, Braunwald E (1980) Calcium channel blocking agents in the treatment of cardiovascular disorders. II. Hemodynamic effects and clinical applications. Ann Intern Med 93: 886–904PubMedGoogle Scholar
  316. Stopher DA, Bereford AP, Macrae PV, Humphrey MJ (1988) The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 12 [suppl 7]: S55–S59PubMedGoogle Scholar
  317. Stressmann J, Leibel B, Vagil Y, Eliakim R, Ben-Ishay D (1985) Nifedipin in the treatment of hypertension in the elderly. J Clin Pharmacol 25: 193Google Scholar
  318. Striessing J, Scheffauer F, Mittendorfer J, Schirmer M, Glossmann H (1990) Identification of the benzothiazepine-binding polypeptide of skeletal muscle calcium channels with (+)-cis-azidodiltiazem and antiligand antibodies. J Biol Chem 265: 363–370Google Scholar
  319. Swedish Multicentre Study Group (1987) Can standard triple treatment of hypertension be replaced by the combination of felodipine with a beta blocker? J Hypertension 4 [suppl 5]: 446–447Google Scholar
  320. Swift CG (1990) Pharmacodynamics: Changes in homeostatic mechanisms, receptor and target organ sensitivity in the elderly. Br Med Bull 46: 36–52PubMedGoogle Scholar
  321. Tabrizchi R, Pang CG, Walker MJ (1989) Effects of anipamil on cardiovascular status and regional blood flow in anestetized rats. Br J Pharmacol 98: 1185–1190PubMedGoogle Scholar
  322. Taburet AM, Singlas E, Colin JN, Banzet O, Thibonnier M, Corvol P (1983) Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects. Hypertension 5 [suppl II]: 29–33Google Scholar
  323. Takabatake T, Yamamoto Y, Nakamura S, Hashimoto N, Satoh S, Yamada Y, Ohta H, Hattori N (1987) Effect of the calcium antagonist nilvadipine on haemodynamics at rest and during cold stimulation in essential hypertension. Eur J Clin Pharmacol 33: 215–219PubMedGoogle Scholar
  324. Terada K, Nakao KK, Okabe K, Kitamura K, Kuriyama H (1987) Action of the 1,4-dihydropyridine derivative, KW-3049, on the smooth muscle membrane of the rabbit mesenteric artery. Br J Pharmacol 92: 615–625PubMedGoogle Scholar
  325. Terakawa M, Tokuma Y, Shishido A, Noguchi H (1987) Pharmacokinetics of nilvadipine in healthy volunteers. J Clin Pharmacol 27: 111–117PubMedGoogle Scholar
  326. Teti A, Grano M, Colucci S, Argentino L, Barattolo R, Miyauchi A, Teitelbaum SL, Hruska KA, Zambonin Zallone A (1989) Voltage dependent calcium channel expression in isolated osteoclasts. Boll Soc Ital Biol Sper 65: 1115–1118PubMedGoogle Scholar
  327. Thananopavarn C, Golub MS, Eggena P, Barett JD, Sambhi MP (1984) Renal effects of nitrendipine monotherapy in essential hypertension. J Cardiovasc Pharmacol 6 [suppl 7]: 1032–1036Google Scholar
  328. Thomas J (1990) The effect of nimodipine on picrotoxin-induced seizures. Brain Res Bull 24: 11–15PubMedGoogle Scholar
  329. Tourkantonis A, Lasaridis A, Settas L (1984) Nitrendipine treatment in essential hypertension. J Cardiovasc Pharmacol 6 [suppl 7]: 1090–1095Google Scholar
  330. Towart R (1981) The selective inhibition of serotonin-induced contractions of rabbit cerebral vascular smooth muscle by calcium antagonistic dihydropyridines. An investigation of the mechanism of action of nifedipine. Circulat Res 48: 650–657PubMedGoogle Scholar
  331. Towart R (1982) Effects of nitrendipine (Bay E 5009), nifedipine, verapamil, phentolamine, papaverine and minoxidil on contractions of isolated rabbit aortic smooth muscle. J Cardiovasc Pharmacol 4: 895–902Google Scholar
  332. Triggle DJ, Janis RA (1984) The 1,4-dihydropyridine receptor; a regulatory component of the calcium channel. J Cardiovasc Pharmacol 6 [suppl 7]: S949–S955PubMedGoogle Scholar
  333. Triggle DJ, Janis RA (1989) Recent development in calcium channel antagonists. Magnesium 8: 213–222PubMedGoogle Scholar
  334. Triggle DJ, Rampe D (1989) 1,4-Dihydropyridine activators and antagonists: structural and functional distinctions. Trends Pharmacol Sci 10: 507–511Google Scholar
  335. Trimarco B, DeLuca N, Ricciardelli B, Volpe M, Veniero A, Cuocolo A, Cicala M (1984) Diltiazem in the treatment of mild or moderate essential hypertension. Comparison with metoprolol in a crossover double-blind trial. J Clin Pharmacol 24: 218–227PubMedGoogle Scholar
  336. Tse FLS, Jaffe JM (1987) Pharmacokinetics of PN 200-110 ( Isradipine), a new calcium antagonist, after oral administration in man. Eur J Clin Pharmacol 32: 361–365PubMedGoogle Scholar
  337. Tuch BE, Osgerby KJ, Turtle JR (1990) The role of calcium in insulin release from human fetal pancreas. Cell Calcium 11: 1–9PubMedGoogle Scholar
  338. Urien S, Albengres E, Comte A, Kiechel J-R, Tillement J-P (1985) Plasma-protein binding and erythrocyte partitioning of nicardipine in vitro. J Cardiovasc Pharmacol 7: 891–898PubMedGoogle Scholar
  339. Van Bortel L, Boehm R, Mooy J, Schiffers P, Rahn KH (1989) Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol 36: 467–471PubMedGoogle Scholar
  340. Van den Berg E, Dehmer GJ (1988) Acute hemodynamic effects of intravenous isradipine. Am J Cardiol 61: 1102–1105PubMedGoogle Scholar
  341. Van Harten J, Burggraaf K, Danhof M, Van Brummelen P, Breimer DD (1987) Negligible subungual absorption of nifedipine. Lancet 11: 1363–1365Google Scholar
  342. Van Harten J, Burggraaf J, Lighthart GJ, van Brummelen P, Breimer DD (1989a) Single- and multiple dose nisoldipine kinetics and effects in the young, the middle aged, and the elderly. Clin Pharmacol Ther 45: 600–607PubMedGoogle Scholar
  343. Van Harten J, Burggraaf J, van Brummelen P, Breimer DD (1989b) Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing. Clin Pharmacokinet 16: 55–64PubMedGoogle Scholar
  344. Van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DD (1988 a) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 43: 332–341Google Scholar
  345. Van Harten J, van Brummelen P, Wilson JH, Lodewijks MT, Breimer DD (1988b) Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. Eur J Clin Pharmacol 34: 387–394PubMedGoogle Scholar
  346. van Amsterdam FT, Punt NC, Haas M, Zaagsma J (1990) Stereoisomers of calcium antagonists distinguish a myocardial and vascular mode of protection against cardiac ischemic injury. J Cardiovasc Pharmacol 15: 198–204PubMedGoogle Scholar
  347. van Zwieten PA (1989) Vascular effects of calcium antagonists: implications for hypertension and other risk factors for coronary heart disease. Am J Cardiol 64: 1171–1211Google Scholar
  348. Vater W, Kroneberg G, Hoffmeister F, Kaller H, Meng K, Oberdorf A, Puis W, Schloßmann K, Stoepel K (1972) Zur Pharmakologie von 4-(2-Nitrophenyl)-2,6-dimethyll,4-dihydropyridin- 3,5 dicarbonsauredimethylester (Nifedipine, Bay a 1040) Arzneimittelforschung 22: 1–14PubMedGoogle Scholar
  349. Vidal S, Raynaud B, Weber MJ (1989) The role of calcium channels of the L-type in neurotransmitter plasticity of cultured sympathetic neurons. Brain Res Mol Brain Res 6: 187–196PubMedGoogle Scholar
  350. Wada Y, Satoh K, Taira N (1985) Separation of the coronary vasodilator from the cardiac effects of PN200-110, a new dihydropyridine calcium antagonist in the dog heart. J Cardiovasc Pharmacol 7: 190–196PubMedGoogle Scholar
  351. Waner T, Nyska A, Bogin E, Levy R, Galiano A (1990) Drug-induced decrease of serum alanine and aspartate aminotransferase activity in the rat, as a result of treatment with oxodipine, a new calcium channel blocker. J Clin Chem Clin Biochem 28: 25–30PubMedGoogle Scholar
  352. Wathen CG, MacLeod D, Tucker L, Muir AL (1984) Felodipine as an alternative to minoxidil in severe refractory hypertension. Drugs 29 [suppl 2]: 157Google Scholar
  353. Wathen CG et al. (1986) Felodipine as replacement for minoxidil in the treatment of severe hypertension. Eur Heart J 7: 893–897PubMedGoogle Scholar
  354. Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC (1988) Once-daily amlodipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 12 [suppl 7]: S72–S75PubMedGoogle Scholar
  355. Wendt B (1982) Pharmacokinetics and metabolism of tiapamil. Cardiology 69 [suppl 1]: 68–78PubMedGoogle Scholar
  356. Westfall MV, Sayeed MM (1990) Effect of calcium channel agonists and antagonists on skeletal muscle sugar transport. Am J Physiol 258: R462–R468PubMedGoogle Scholar
  357. Williams DM, Cubeddu LX (1988) Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 28: 990–994PubMedGoogle Scholar
  358. Wong MC, Haley EC (1990) Calcium antagonists: stroke therapy coming of age. Stroke 21: 494–501PubMedGoogle Scholar
  359. Wood AJ (1989) Calcium antagonists. Pharmacological differences and similarities. Circulation 80 [suppl]:IV184–IV188PubMedGoogle Scholar
  360. Wynsen JC, Shimsack TM, Preuss KC, Hartmann HF, Waritter DC (1987) Cardiovascular actions of a new dihydropyridine calcium antagonist, 8363 S: Comparison with nifedipine and nicardipine in awake, unsedated dogs. J Cardiovasc Pharmacol 10: 30–37PubMedGoogle Scholar
  361. Yamada S, Kimura R, Harada Y, Nakayama K (1990) Calcium channel receptor sites for (+)-3H-PN 200-110 in coronary artery. J Pharmacol Ther 252: 327–332Google Scholar
  362. Yamamura HI, Schoemaker H, Boles RG, Roeske WR (1982) Diltiazem enhancement of 3H- nitrendipine binding to calcium channel-associated drug receptor sites in rat brain synaptosomes. Biochem Biophys Res Commun 108: 604Google Scholar
  363. Yokota M, Koide M, Miyahara T, Kamihara A, Tsunekawa S, Noda S, Sotobata I (1987) Effects of a new second generation calcium channel blocker, nilvadipine (FR 34235), on exercise-induced hemodynamic changes in stable angina pectoris. J Am Coll Cardiol 10: 830–836PubMedGoogle Scholar
  364. Yokoyama K, Yagasaki O (1990) Effects of Calcium blockers on the various types of stimuliinduced acetylcholine release from guinea pig ileum myenteric plexus. Jpn J Pharmacol 52: 109–114PubMedGoogle Scholar
  365. Zachariah PK, Sheps SG, Oshrain C, Schirger A, Stein WJ (1987) Antihypertensive efficacy of sustained-release verapamil. J Clin Hypertens 3: 536–546PubMedGoogle Scholar
  366. Zernig G (1990) Widening potential for calcium antagonists: non-L-type Ca2+-channel interaction. Trends Pharmacol Sci 11: 38–44PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • E. Fritschka
  • M. Claus
  • Th. Philipp

There are no affiliations available

Personalised recommendations